← Back to Search

Monoclonal Antibodies

Combination of Ozurdex and Eylea for Diabetic Macular Edema

Phase 4
Recruiting
Led By Ashkan M Abbey, MD
Research Sponsored by Texas Retina Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks, 24 weeks, 36 weeks, and 48 weeks
Awards & highlights

Study Summary

The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial (COED Trial)

Eligible Conditions
  • Diabetic Macular Edema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks, 24 weeks, 36 weeks, and 48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks, 24 weeks, 36 weeks, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Central Subfield Thickness (CST)
Secondary outcome measures
Best Corrected Visual Acuity (BCVA)
CST
Monthly mean changes from baseline in BCVA
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Combination of Ozurdex and EyleaExperimental Treatment2 Interventions
Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
Group II: Eylea MonotherapyActive Control1 Intervention
Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aflibercept
FDA approved
Dexamethasone
FDA approved

Find a Location

Who is running the clinical trial?

The Emmes Company, LLCIndustry Sponsor
145 Previous Clinical Trials
1,051,441 Total Patients Enrolled
Texas Retina AssociatesLead Sponsor
5 Previous Clinical Trials
230 Total Patients Enrolled
Ashkan M Abbey, MDPrincipal InvestigatorTexas Retina Associates

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~9 spots leftby May 2025